PMCC Staff Publications

pmcc logo sml



Here are the staff publications for October 2019.

Compiled by the Health Sciences Library (RMH, RWH, PMCC & Victorian Mental Health) 12th November 2019.


1. Correction to Lancet Oncol 2019; 20: 1273-85. Lancet Oncology 2019;20:e468.

2. Bauer TM, Felip E, Solomon BJ, Thurm H, Peltz G, Chioda MD, Shaw AT. Clinical Management of Adverse Events Associated with Lorlatinib. Oncologist 2019;24:1103-10.

3. Bell SW, Heriot AG, Warrier SK, Farmer CK, Stevenson ARL, Bissett I, Kong JC, Solomon M. Surgical techniques in the management of rectal cancer: a modified Delphi method by colorectal surgeons in Australia and New Zealand. Techniques in Coloproctology 2019;23:743-9.

4. Berger I, Thompson K, Joubert L. An Exploratory Study into the Experience of Health Care Professionals Caring for Adolescents and Young Adults with Incurable Cancer. Journal of Adolescent and Young Adult Oncology 2019;8:458-62.

5. Blombery P, Birkinshaw RW, Nguyen T, Gong JN, Thompson ER, Xu Z, Westerman DA, Czabotar PE, Dickinson M, Huang DCS, Seymour JF, Roberts AW. Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma. British Journal of Haematology 2019;186:e188-e91.

6. Bodelon C, Killian JK, Sampson JN, Anderson WF, Matsuno R, Brinton LA, Lissowska J, Anglesio MS, Bowtell DDL, Doherty JA, Ramus SJ, Talhouk A, Sherman ME, Wentzensen N. Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity. Clinical Cancer Research 2019;25:5937-46.

7. Bucknell NW, Dixon BJ, Hoffman MS, McDowell LJ. Importance of timing in staging head and neck cancer: cervical adenopathy post-tonsillectomy mimicking malignancy. ANZ Journal of Surgery 2019;89:1167-9.

8. Burr ML, Sparbier CE, Chan KL, Chan YC, Kersbergen A, Lam EYN, Azidis-Yates E, Vassiliadis D, Bell CC, Gilan O, Jackson S, Tan L, Wong SQ, Hollizeck S, Michalak EM, Siddle HV, McCabe MT, Prinjha RK, Guerra GR, Solomon BJ, Sandhu S, Dawson SJ, Beavis PA, Tothill RW, Cullinane C, Lehner PJ, Sutherland KD, Dawson MA. An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell 2019;36:385-401.e8.

9. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Fendler WP, Czernin J. What is the best PET target for early biochemical recurrence of prostate cancer?-Authors' reply. Lancet Oncology 2019;20:e609-e10.

10. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncology 2019;20:1286-94.

11. Campbell BA, Hofman MS, Prince HM. A Novel Application of [18F]Fluorothymidine-PET ([18F]FLT-PET) in Clinical Practice to Quantify Regional Bone Marrow Function in a Patient With Treatment-Induced Cytopenias and to Guide "Marrow-Sparing" Radiotherapy. Clinical Nuclear Medicine 2019;44:e624-e6.

12. Casswell G, Cavanagh K, Ravi Kumar AS, Giddings C, McDowell L. Setting the stage: Contemporary staging of non-melanomatous skin cancer and implementation of the new American Joint Committee on cancer eighth edition staging manual. Oral Oncology 2019;98:102-8.

13. Charnley M, Ludford-Menting M, Pham K, Russell SM. A new role for Notch in the control of polarity and asymmetric cell division of developing T cells. Journal of Cell Science 2019;133.

14. Christiansen D, Mouhtouris E, Hodgson R, Sutton VR, Trapani JA, Ierino FL, Sandrin MS. Antigen-specific CD4(+) CD25(+) T cells induced by locally expressed ICOS-Ig: the role of Foxp3, Perforin, Granzyme B and IL-10 - an experimental study. Transplant International 2019;32:1203-15.

15. Craike M, Bourke M, Hilland TA, Wiesner G, Pascoe MC, Bengoechea EG, Parker AG. Correlates of Physical Activity Among Disadvantaged Groups: A Systematic Review. American Journal of Preventive Medicine 2019;57:700-15. 

16. de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Jurgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen RF, Smit V, Singh N, Do V, Lissoni A, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL, Group PS. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncology 2019;20:1273-85.

17. Doidge O, Edwards N, Thompson K, Lewin J. A Conceptual Framework to Identify and Address the Education and Vocational Barriers Experienced by Adolescents and Young Adults with Cancer. Journal of Adolescent and Young Adult Oncology 2019;8:398-401.

18. Dunn A, Johnstone RW, Stillman B. Joseph F. Sambrook (1939-2019). Nature Structural & Molecular Biology 2019;26:846-7.

19. Esposito D, Weile J, Shendure J, Starita LM, Papenfuss AT, Roth FP, Fowler DM, Rubin AF. MaveDB: an open-source platform to distribute and interpret data from multiplexed assays of variant effect. Genome Biology 2019;20:223.

20. Gao C, McCormack C, van der Weyden C, Goh MS, Campbell BA, Twigger R, Buelens O, Harrison SJ, Khoo C, Lade S, Prince HM. Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sezary syndrome. Blood 2019;134:1346-50.

21. Goel S, Tolaney SM. CDK4/6 inhibitors in breast cancer: a role in triple-negative disease? Lancet Oncology 2019;20:1479-81.

22. Grech LB, Butler E, Stuckey S, Hester R. Letter to the editor: FLOUX-PMS study sample considerations. Multiple Sclerosis 2019;25:1819-20.

23. Green EM, Blunck Y, Tahayori B, Farrell PM, Korte JC, Johnston LA. Spin Lock Adiabatic Correction (SLAC) for B1-insensitive pulse design at 7T. Journal of Magnetic Resonance 2019;308:106595.

24. Hanna B, Ranasinghe W, Lawrentschuk N. Risk stratification and avoiding overtreatment in localized prostate cancer. Current Opinion in Urology 2019;29:612-9.

25. Hasmat S, Ebrahimi A, Luk PP, Low TH, McDowell L, Magarey MJR, Veness M, Gupta R, Clark J. Positive survival trend in metastatic head and neck cutaneous squamous cell carcinoma over four-decades: Multicenter study. Head and Neck 2019;41:3826-32.

26. Hellmann MD, Kim TW, Lee CB, Goh BC, Miller WH, Oh DY, Jamal R, Chee CE, Chow LQM, Gainor JF, Desai J, Solomon BJ, Das Thakur M, Pitcher B, Foster P, Hernandez G, Wongchenko MJ, Cha E, Bang YJ, Siu LL, Bendell J. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. Annals of Oncology 2019;30:1134-42.

27. Hewson EA, Nguyen DT, O'Brien R, Kim JH, Montanaro T, Moodie T, Greer PB, Hardcastle N, Eade T, Kneebone A, Hruby G, Hayden AJ, Turner S, Siva S, Tai KH, Hunter P, Sams J, Poulsen PR, Booth JT, Martin J, Keall PJ. The accuracy and precision of the KIM motion monitoring system used in the multi-institutional TROG 15.01 Stereotactic Prostate Ablative Radiotherapy with KIM (SPARK) trial. Medical Physics 2019;46:4725-37.

28. Holt NR, Downey G, Naughton MT. Perioperative considerations in the management of obstructive sleep apnoea. Medical Journal of Australia 2019;211:326-32.

29. Ierano C, Thursky K, Marshall C, Koning S, James R, Johnson S, Imam N, Worth LJ, Peel T. Appropriateness of Surgical Antimicrobial Prophylaxis Practices in Australia. JAMA Network Open 2019;2:e1915003.

30. Kapoor J, Koschel S, Murphy DG. Editorial Comment. Journal of Urology 2019;202:1180-1.

31. Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. New England Journal of Medicine 2019;381:1632-43.

32. Koschel S, Murphy DG, Hofman MS, Wong LM. The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer. Current Opinion in Urology 2019;29:569-77.

33. Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schoder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K. EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177)Lu-PSMA-RLT). European Journal of Nuclear Medicine and Molecular Imaging 2019;46:2536-44.

34. Laitman Y, Friebel TM, Yannoukakos D, Fostira F, Konstantopoulou I, Figlioli G, Bonanni B, Manoukian S, Zuradelli M, Tondini C, Pasini B, Peterlongo P, Plaseska-Karanfilska D, Jakimovska M, Majidzadeh K, Zarinfam S, Loizidou MA, Hadjisavvas A, Michailidou K, Kyriacou K, Behar DM, Molho RB, Ganz P, James P, Parsons MT, Sallam A, Olopade OI, Seth A, Chenevix-Trench G, Leslie G, McGuffog L, Marafie MJ, Megarbane A, Al-Mulla F, Rebbeck TR, Friedman E. The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries. Human Mutation 2019;40:e1-e23.

35. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Marquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schoffski P, Carlino MS, Lebbe C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine 2019;381:1535-46.

36. Lewis KD, Larkin J, Ribas A, Flaherty KT, McArthur GA, Ascierto PA, Dreno B, Yan Y, Wongchenko M, McKenna E, Zhu Q, Mun Y, Hauschild A. Impact of depth of response on survival in patients treated with cobimetinib +/- vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. British Journal of Cancer 2019;121:522-8.

37. Licqurish SM, Cook OY, Pattuwage LP, Saunders C, Jefford M, Koczwara B, Johnson CE, Emery JD. Tools to facilitate communication during physician-patient consultations in cancer care: An overview of systematic reviews. CA: A Cancer Journal for Clinicians 2019;69:497-520.

38. Lindsay J, Teh BW, Micklethwaite K, Slavin M. Azole antifungals and new targeted therapies for hematological malignancy. Current Opinion in Infectious Diseases 2019;32:538-45.

39. Lisy K, Langdon L, Piper A, Jefford M. Identifying the most prevalent unmet needs of cancer survivors in Australia: A systematic review. Asia Pacific Journal of Clinical Oncology 2019;15:e68-e78.

40. Metser U, Chua S, Ho B, Punwani S, Johnston E, Pouliot F, Tau N, Hawsawy A, Anconina R, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Pond G, Scott AM, Tunariu N, Sidhu H, Emmett L. The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of (18)F-Fluoromethylcholine or (68)Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. Journal of Nuclear Medicine 2019;60:1253-8.

41. Miles LF, Burbury KL, Story DA. Selecting and optimising patients for total knee arthroplasty. Medical Journal of Australia 2019;211:285- e1.

42. Morris TA, Khoo C, Solomon BJ. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors. Drugs 2019;79:1277-86.

43. Narasimhan V, Das A, Warrier S, Lynch C, McCormick J, Tie J, Michael M, Ramsay R, Heriot A. Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases. Langenbeck's Archives of Surgery 2019;404:527-39.

44. Narasimhan V, Pham T, Warrier S, Craig Lynch A, Michael M, Tie J, Ramsay R, Heriot A. Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms. ANZ Journal of Surgery 2019;89:1035-40.

45. Ng ZY, Bishton M, Ritchie D, Campbell R, Gilbertson M, Hill K, Ratnasingam S, Schwarer A, Manos K, Shorten S, Ng M, Nelson N, Xin L, De Mel Widanalage S, Sunny T, Purtill D, Poon M, Johnston A, Cochrane T, Lee HP, Hapgood G, Tam C, Opat S, Hawkes E, Seymour J, Cheah CY. A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma. Hematological Oncology 2019;37:253-60.

46. Nones K, Johnson J, Newell F, Patch AM, Thorne H, Kazakoff SH, de Luca XM, Parsons MT, Ferguson K, Reid LE, McCart Reed AE, Srihari S, Lakis V, Davidson AL, Mukhopadhyay P, Holmes O, Xu Q, Wood S, Leonard C, Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast C, Australian Breast Cancer Tissue B, Brisbane Breast B, Beesley J, Harris JM, Barnes D, Degasperi A, Ragan MA, Spurdle AB, Khanna KK, Lakhani SR, Pearson JV, Nik-Zainal S, Chenevix-Trench G, Waddell N, Simpson PT. Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers. Annals of Oncology 2019;30:1071-9.

47. O'Leary B, Hrebien S, Beaney M, Fribbens C, Garcia-Murillas I, Jiang J, Li Y, Huang Bartlett C, Andre F, Loibl S, Loi S, Cristofanilli M, Turner NC. Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. Clinical Chemistry 2019;65:1405-13.

48. Osborn M, Johnson R, Thompson K, Anazodo A, Albritton K, Ferrari A, Stark D. Models of care for adolescent and young adult cancer programs. Pediatric Blood & Cancer 2019;66:e27991.

49. Parsons MT, Tudini E, Li H, Hahnen E, Wappenschmidt B, Feliubadalo L, Aalfs CM, Agata S, Aittomaki K, Alducci E, Alonso-Cerezo MC, Arnold N, Auber B, Austin R, Azzollini J, Balmana J, Barbieri E, Bartram CR, Blanco A, Blumcke B, Bonache S, Bonanni B, Borg A, Bortesi B, Brunet J, Bruzzone C, Bucksch K, Cagnoli G, Caldes T, Caliebe A, Caligo MA, Calvello M, Capone GL, Caputo SM, Carnevali I, Carrasco E, Caux-Moncoutier V, Cavalli P, Cini G, Clarke EM, Concolino P, Cops EJ, Cortesi L, Couch FJ, Darder E, de la Hoya M, Dean M, Debatin I, Del Valle J, Delnatte C, Derive N, Diez O, Ditsch N, Domchek SM, Dutrannoy V, Eccles DM, Ehrencrona H, Enders U, Evans DG, Farra C, Faust U, Felbor U, Feroce I, Fine M, Foulkes WD, Galvao HCR, Gambino G, Gehrig A, Gensini F, Gerdes AM, Germani A, Giesecke J, Gismondi V, Gomez C, Gomez Garcia EB, Gonzalez S, Grau E, Grill S, Gross E, Guerrieri-Gonzaga A, Guillaud-Bataille M, Gutierrez-Enriquez S, Haaf T, Hackmann K, Hansen TVO, Harris M, Hauke J, Heinrich T, Hellebrand H, Herold KN, Honisch E, Horvath J, Houdayer C, Hubbel V, Iglesias S, Izquierdo A, James PA, Janssen LAM, Jeschke U, Kaulfuss S, Keupp K, Kiechle M, Kolbl A, Krieger S, Kruse TA, Kvist A, Lalloo F, Larsen M, Lattimore VL, Lautrup C, Ledig S, Leinert E, Lewis AL, Lim J, Loeffler M, Lopez-Fernandez A, Lucci-Cordisco E, Maass N, Manoukian S, Marabelli M, Matricardi L, Meindl A, Michelli RD, Moghadasi S, Moles-Fernandez A, Montagna M, Montalban G, Monteiro AN, Montes E, Mori L, Moserle L, Muller CR, Mundhenke C, Naldi N, Nathanson KL, Navarro M, Nevanlinna H, Nichols CB, Niederacher D, Nielsen HR, Ong KR, Pachter N, Palmero EI, Papi L, Pedersen IS, Peissel B, Perez-Segura P, Pfeifer K, Pineda M, Pohl-Rescigno E, Poplawski NK, Porfirio B, Quante AS, Ramser J, Reis RM, Revillion F, Rhiem K, Riboli B, Ritter J, Rivera D, Rofes P, Rump A, Salinas M, Sanchez de Abajo AM, Schmidt G, Schoenwiese U, Seggewiss J, Solanes A, Steinemann D, Stiller M, Stoppa-Lyonnet D, Sullivan KJ, Susman R, Sutter C, Tavtigian SV, Teo SH, Teule A, Thomassen M, Tibiletti MG, Tischkowitz M, Tognazzo S, Toland AE, Tornero E, Torngren T, Torres-Esquius S, Toss A, Trainer AH, Tucker KM, van Asperen CJ, van Mackelenbergh MT, Varesco L, Vargas-Parra G, Varon R, Vega A, Velasco A, Vesper AS, Viel A, Vreeswijk MPG, Wagner SA, Waha A, Walker LC, Walters RJ, Wang-Gohrke S, Weber BHF, Weichert W, Wieland K, Wiesmuller L, Witzel I, Wockel A, Woodward ER, Zachariae S, Zampiga V, Zeder-Goss C, Investigators K, Lazaro C, De Nicolo A, Radice P, Engel C, Schmutzler RK, Goldgar DE, Spurdle AB. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Human Mutation 2019;40:1557-78.

50. Peacock O, Waters PS, Bressel M, Lynch AC, Wakeman C, Eglinton T, Koh CE, Lee PJ, Austin KK, Warrier SK, Solomon MJ, Frizelle FA, Heriot AG. Prognostic factors and patterns of failure after surgery for T4 rectal cancer in the beyond total mesorectal excision era. British Journal of Surgery 2019;106:1685-96.

51. Pham T, Pereira L, Roth S, Galletta L, Link E, Akhurst T, Solomon B, Michael M, Darcy P, Sampurno S, Heriot A, Ramsay R, Desai J. First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427). Contemp Clin Trials Commun 2019;16:100409.

52. Rahbar K, Hofman MS, Schrader AJ, Bogemann M. A Self-Fulfilling Prophecy: Comparing (177)Lu-PSMA Radioligand Therapy in Taxane-Naive Versus Posttaxane Metastasized Prostate Cancer Patients? Journal of Nuclear Medicine 2019;60:1494.

53. Sathianathen NJ, Jarosek S, Lawrentschuk N, Bolton D, Konety BR. A Simplified Frailty Index to Predict Outcomes After Radical Cystectomy. European Urology Focus 2019;5:658-63.

54. Sharma VJ, Gupta A, Yaftian N, Ball D, Brown R, Barnett S, Antippa P. Low recurrence of lung adenoid cystic carcinoma with radiotherapy and resection. ANZ Journal of Surgery 2019;89:1051-5.

55. Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Annals of Oncology 2019;30:1121-6.

56. Sheppard KE, AbuHammad S. CDK4/6 inhibition in cancer: the cell cycle splicing connection. Molecular & Cellular Oncology 2019;6:e1673643.

57. Stover EH, Baco MB, Cohen O, Li YY, Christie EL, Bagul M, Goodale A, Lee Y, Pantel S, Rees MG, Wei G, Presser AG, Gelbard MK, Zhang W, Zervantonakis IK, Bhola PD, Ryan J, Guerriero JL, Montero J, Liang FJ, Cherniack AD, Piccioni F, Matulonis UA, Bowtell DDL, Sarosiek KA, Letai A, Garraway LA, Johannessen CM, Meyerson M. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. Molecular Cancer Research 2019;17:2281-93.

58. Talwelkar SS, Nagaraj AS, Devlin JR, Hemmes A, Potdar S, Kiss EA, Saharinen P, Salmenkivi K, Mayranpaa MI, Wennerberg K, Verschuren EW. Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers. Molecular Cancer Therapeutics 2019;18:1863-74.

59. Thijssen R, Roberts AW. Venetoclax in Lymphoid Malignancies: New Insights, More to Learn. Cancer Cell 2019;36:341-3.

60. Tino R, Leary M, Yeo A, Brandt M, Kron T. Gyroid structures for 3D-printed heterogeneous radiotherapy phantoms. Physics in Medicine and Biology 2019;64:21nt05.

61. Tobin JWD, Rule G, Colvin K, Calvente L, Hodgson D, Bell S, Dunduru C, Gallo J, Tsang ES, Tan X, Wong J, Pearce J, Campbell R, Tneh S, Shorten S, Ng M, Cochrane T, Tam CS, Abro E, Hawkes E, Hodges G, Kansara R, Talaulikar D, Gilbertson M, Johnston AM, Savage KJ, Villa D, Morris K, Ratnasingam S, Janowski W, Kridel R, Cheah CY, MacManus M, Matigian N, Mollee P, Gandhi MK, Hapgood G. Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. Blood Advances 2019;3:2804-11.

62. Toppi J, Webb A. Locally recurrent lentigo maligna within a skin graft: a case report. ANZ Journal of Surgery 2019;89:1161-2.

63. Utitsarn K, Biasi G, Stansook N, Alrowaili ZA, Petasecca M, Carolan M, Perevertaylo VL, Tome WA, Kron T, Lerch MLF, Rosenfeld AB. Two-dimensional solid-state array detectors: A technique for in vivo dose verification in a variable effective area. Journal of Applied Clinical Medical Physics 2019;20:88-94.

64. Vodanovich DA, Spelman T, May D, Slavin J, Choong PFM. Predicting the prognosis of undifferentiated pleomorphic soft tissue sarcoma: a 20-year experience of 266 cases. ANZ Journal of Surgery 2019;89:1045-50.

65. Zia NA, Cullinane C, Van Zuylekom JK, Waldeck K, McInnes LE, Buncic G, Haskali MB, Roselt PD, Hicks RJ, Donnelly PS. A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention. Angewandte Chemie (International ed in English) 2019;58:14991-4.